SK Group bets on biotechnology as energy business slows

Korean conglomerate SK Group plans to spend $1 billion to build a biotechnology business, which it hopes will offset slow growth in its existing businesses.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES